These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16887485)

  • 21. Neutron brachytherapy for the treatment of malignant neoplasia.
    Maruyama Y
    Int J Radiat Oncol Biol Phys; 1988 Dec; 15(6):1415-29. PubMed ID: 3058659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical physics aspects of particle therapy.
    Jäkel O
    Radiat Prot Dosimetry; 2009 Nov; 137(1-2):156-66. PubMed ID: 19828718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.
    Suit H; Kooy H; Trofimov A; Farr J; Munzenrider J; DeLaney T; Loeffler J; Clasie B; Safai S; Paganetti H
    Radiother Oncol; 2008 Feb; 86(2):148-53. PubMed ID: 18237800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The first century of cancer chemotherapy.
    Hellman S
    J Clin Oncol; 1998 Jul; 16(7):2295-6. PubMed ID: 9667241
    [No Abstract]   [Full Text] [Related]  

  • 25. Trials and tribulations in charged particle radiotherapy.
    Goitein M
    Radiother Oncol; 2010 Apr; 95(1):23-31. PubMed ID: 19581014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secondary neutrons in clinical proton radiotherapy: a charged issue.
    Brenner DJ; Hall EJ
    Radiother Oncol; 2008 Feb; 86(2):165-70. PubMed ID: 18192046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose calculation in biological samples in a mixed neutron-gamma field at the TRIGA reactor of the University of Mainz.
    Schmitz T; Blaickner M; Schütz C; Wiehl N; Kratz JV; Bassler N; Holzscheiter MH; Palmans H; Sharpe P; Otto G; Hampel G
    Acta Oncol; 2010 Oct; 49(7):1165-9. PubMed ID: 20831509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Some considerations of physical and biological factors in radiotherapy with high-LET radiations including heavy particles, pi mesons, and fast neutrons.
    Tobias CA; Lyman JT; Lawrence JH
    Prog At Med; 1971; 3():167-218. PubMed ID: 5004402
    [No Abstract]   [Full Text] [Related]  

  • 29. The clinical experience with particle therapy in adults.
    Schulz-Ertner D
    Cancer J; 2009; 15(4):306-11. PubMed ID: 19672147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there any future for high-LET radiation?
    Wambersie A
    Strahlenther Onkol; 1989 Apr; 165(4):348-56. PubMed ID: 2540543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physical and Biological Characteristics of Particle Therapy for Oncologists.
    Byun HK; Han MC; Yang K; Kim JS; Yoo GS; Koom WS; Kim YB
    Cancer Res Treat; 2021 Jul; 53(3):611-620. PubMed ID: 34139805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction between the biological effects of high- and low-LET radiation dose components in a mixed field exposure.
    Mason AJ; Giusti V; Green S; Munck af Rosenschöld P; Beynon TD; Hopewell JW
    Int J Radiat Biol; 2011 Dec; 87(12):1162-72. PubMed ID: 21923301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison doses of secondary neutron with the heavy ions in a 75-Mev/n heavy ion beam.
    Dang B; Li W; Wang J
    Radiat Prot Dosimetry; 2005; 117(4):369-72. PubMed ID: 16046558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Shielding design for a laser-accelerated proton therapy system.
    Fan J; Luo W; Fourkal E; Lin T; Li J; Veltchev I; Ma CM
    Phys Med Biol; 2007 Jul; 52(13):3913-30. PubMed ID: 17664585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutron brachytherapy in the modern era: Indications and evidence.
    Loap P; Barcellini A; de Marzi L; Orlandi E; Kirova Y
    Cancer Radiother; 2023 Apr; 27(2):170-177. PubMed ID: 36759242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A model for the relative biological effectiveness of protons: the tissue specific parameter α/β of photons is a predictor for the sensitivity to LET changes.
    Wedenberg M; Lind BK; Hårdemark B
    Acta Oncol; 2013 Apr; 52(3):580-8. PubMed ID: 22909391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Boron neutron capture a a new radiotherapy model].
    Hideghéty K; Sauerwwein W; Rassuw J; Sack H
    Orv Hetil; 1998 Mar; 139(12):675-9. PubMed ID: 9555163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Neutron flow measurements in the d(14) + Be neutron radiation field from the cyclotron in Essen].
    Pöller F; Sauerwein W; Rau D; Wagner FM; Olthoff K; Rassow J; Sack H
    Strahlenther Onkol; 1990 Jun; 166(6):426-9. PubMed ID: 2363106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Particle radiation therapy: current status and future potential.
    Parker RG
    Cancer; 1977 Feb; 39(2 Suppl):802-5. PubMed ID: 402196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. One hundred years of radiotherapy in Turkey.
    Dincer M; Kuter S
    Lancet Oncol; 2001 Oct; 2(10):631-3. PubMed ID: 11902554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.